DIS3L2
Basic information
Region (hg38): 2:231961245-232344350
Previous symbols: [ "FAM6A" ]
Links
Phenotypes
GenCC
Source:
- Perlman syndrome (Definitive), mode of inheritance: AR
- Perlman syndrome (Supportive), mode of inheritance: AR
- Perlman syndrome (Strong), mode of inheritance: AR
- Perlman syndrome (Definitive), mode of inheritance: AR
Clinical Genomic Database
Source:
| Condition | Inheritance | Intervention Categories | Intervention/Rationale | Manifestation Categories | References |
|---|---|---|---|---|---|
| Perlman syndrome | AR | Oncologic | Individuals have a high risk of Wilms tumor, and surveillance may allow early detection and treatment, which may be beneficial | Craniofacial; Musculoskeletal; Neurologic; Oncologic; Renal | 4315293; 163679; 6093533; 3024486; 10508986; 22306653; 22705997; 23486540; 23613427 |
ClinVar
This is a list of variants' phenotypes submitted to
- Perlman_syndrome (2137 variants)
- not_provided (134 variants)
- Inborn_genetic_diseases (118 variants)
- DIS3L2-related_disorder (67 variants)
- not_specified (13 variants)
- Neurodevelopmental_disorder (1 variants)
- Nephroblastoma (1 variants)
- Hepatoblastoma (1 variants)
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the DIS3L2 gene is commonly pathogenic or not. These statistics are base on transcript: NM_000152383.5. Only rare variants are included in the table.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
| Effect | PathogenicP | Likely pathogenicLP | VUSVUS | Likely benignLB | BenignB | Sum |
|---|---|---|---|---|---|---|
| synonymous | 13 | 491 | 507 | |||
| missense | 1100 | 18 | 1124 | |||
| nonsense | 14 | 27 | ||||
| start loss | 2 | 2 | ||||
| frameshift | 31 | 14 | 13 | 58 | ||
| splice donor/acceptor (+/-2bp) | 21 | 24 | ||||
| Total | 49 | 45 | 1133 | 509 | 6 |
Highest pathogenic variant AF is 0.000006818035
GnomAD
Source:
| Gene | Type | Bio Type | Transcript | Coding Exons | Length |
|---|---|---|---|---|---|
| DIS3L2 | protein_coding | protein_coding | ENST00000325385 | 20 | 383106 |
| pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
|---|---|---|---|---|---|---|
| 0.944 | 0.0560 | 124784 | 0 | 18 | 124802 | 0.0000721 |
| Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
|---|---|---|---|---|---|---|
| Missense | 0.944 | 477 | 539 | 0.886 | 0.0000329 | 5782 |
| Missense in Polyphen | 126 | 189.62 | 0.66448 | 1938 | ||
| Synonymous | -0.174 | 222 | 219 | 1.01 | 0.0000145 | 1729 |
| Loss of Function | 5.06 | 8 | 44.4 | 0.180 | 0.00000238 | 513 |
LoF frequencies by population
| Ethnicity | Sum of pLOFs | p |
|---|---|---|
| African & African-American | 0.0000651 | 0.0000645 |
| Ashkenazi Jewish | 0.0000993 | 0.0000993 |
| East Asian | 0.000338 | 0.000334 |
| Finnish | 0.0000464 | 0.0000464 |
| European (Non-Finnish) | 0.0000710 | 0.0000706 |
| Middle Eastern | 0.000338 | 0.000334 |
| South Asian | 0.0000327 | 0.0000327 |
| Other | 0.00 | 0.00 |
dbNSFP
Source:
- Function
- FUNCTION: 3'-5'-exoribonuclease that specifically recognizes RNAs polyuridylated at their 3' end and mediates their degradation. Component of an exosome-independent RNA degradation pathway that mediates degradation of both mRNAs and miRNAs that have been polyuridylated by a terminal uridylyltransferase, such as ZCCHC11/TUT4. Mediates degradation of cytoplasmic mRNAs that have been deadenylated and subsequently uridylated at their 3'. Mediates degradation of uridylated pre-let-7 miRNAs, contributing to the maintenance of embryonic stem (ES) cells. Essential for correct mitosis, and negatively regulates cell proliferation. {ECO:0000255|HAMAP-Rule:MF_03045, ECO:0000269|PubMed:23756462, ECO:0000269|PubMed:24141620}.;
- Disease
- DISEASE: Perlman syndrome (PRLMNS) [MIM:267000]: An autosomal recessive congenital overgrowth syndrome. Affected children are large at birth, are hypotonic, and show organomegaly, characteristic facial dysmorphisms (inverted V-shaped upper lip, prominent forehead, deep-set eyes, broad and flat nasal bridge, and low-set ears), renal anomalies (nephromegaly and hydronephrosis), frequent neurodevelopmental delay, and high neonatal mortality. Perlman syndrome is associated with a high risk of Wilms tumor. Histologic examination of the kidneys in affected children shows frequent nephroblastomatosis, which is a precursor lesion for Wilms tumor. {ECO:0000269|PubMed:22306653, ECO:0000269|PubMed:23486540, ECO:0000269|PubMed:23613427, ECO:0000269|PubMed:28328139}. Note=The disease is caused by mutations affecting the gene represented in this entry.;
Recessive Scores
- pRec
- 0.0906
Intolerance Scores
- loftool
- 0.559
- rvis_EVS
- -0.28
- rvis_percentile_EVS
- 33.53
Haploinsufficiency Scores
- pHI
- 0.0694
- hipred
- N
- hipred_score
- 0.414
- ghis
- 0.432
Essentials
- essential_gene_CRISPR
- N
- essential_gene_CRISPR2
- N
- essential_gene_gene_trap
- N
- gene_indispensability_pred
- E
- gene_indispensability_score
- 0.873
Gene Damage Prediction
| All | Recessive | Dominant | |
|---|---|---|---|
| Mendelian | Medium | Medium | Medium |
| Primary Immunodeficiency | Medium | Medium | Medium |
| Cancer | Medium | Medium | Medium |
Mouse Genome Informatics
- Gene name
- Dis3l2
- Phenotype
Zebrafish Information Network
- Gene name
- dis3l2
- Affected structure
- pronephric duct opening
- Phenotype tag
- abnormal
- Phenotype quality
- morphology
Gene ontology
- Biological process
- mitotic cell cycle;nuclear-transcribed mRNA catabolic process, exonucleolytic;rRNA processing;RNA catabolic process;negative regulation of cell population proliferation;miRNA catabolic process;stem cell population maintenance;nuclear-transcribed mRNA catabolic process, exonucleolytic, 3'-5';cell division;mitotic sister chromatid separation;RNA phosphodiester bond hydrolysis, exonucleolytic;polyuridylation-dependent mRNA catabolic process
- Cellular component
- exosome (RNase complex);P-body;cytoplasm;polysome
- Molecular function
- 3'-5'-exoribonuclease activity;magnesium ion binding;ribonuclease activity;protein binding;poly(U) RNA binding